Valuation: SpectraCure AB

Market Cap 2.05Cr 21.54L 18.6L 17.48L 15.9L 29.89L 21Cr 30.39L 80.09L 10Cr 80.87L 79.12L 34Cr P/E 2024
-10.6x
P/E 2025 -0.79x
Enterprise Value 97.49L 10.25L 9L 8L 8L 14.23L 9.8Cr 14.46L 38.12L 4.91Cr 38.49L 37.65L 16Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
28.39%
Yield 2024 *
-
Yield 2025 -
1 day-7.47%
1 week-5.53%
Current month+8.13%
1 month-11.79%
3 months-41.53%
6 months-65.48%
Current year-76.96%
1 week 0.04
Extreme 0.035
0.04
1 month 0.03
Extreme 0.0302
0.05
Current year 0.03
Extreme 0.0302
0.17
1 year 0.03
Extreme 0.0302
0.32
3 years 0.03
Extreme 0.0302
5.44
5 years 0.03
Extreme 0.0302
11.28
10 years 0.03
Extreme 0.0302
45.15
Manager TitleAgeSince
Chief Executive Officer 54 01/10/2025
Director of Finance/CFO - 01/06/2026
Chief Tech/Sci/R&D Officer - 07/10/2025
Director TitleAgeSince
Director/Board Member 63 31/08/2012
Director/Board Member 72 01/01/2022
Chairman 74 01/01/2022
Date Insider Type Main position Quantity % Market Cap.
26/05/23 Buy

Chairman

25,000 0.0257%
30/08/22 Buy

Director

25,000 0.0257%
09/07/22 Sell

Director

10,48,493 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
-7.47%-5.53%-76.63%-99.27% 21.54L
-0.38%-3.10%+32.37%+48.34% 144.95Cr
-1.83%-3.60%-14.40%-46.39% 5.26Cr
Average -3.23%-0.18%-19.55%-32.44% 50.14Cr
Weighted average by Cap. -0.44%-1.51%+30.58%+44.81%

Financials

2024 2025
Net sales - -
Net income -2.3Cr -24.19L -20.89L -19.63L -17.86L -33.57L -23Cr -34.12L -89.94L -12Cr -90.82L -88.85L -38Cr -5.61Cr -58.97L -50.93L -47.86L -43.53L -81.83L -56Cr -83.18L -2.19Cr -28Cr -2.21Cr -2.17Cr -94Cr
Net Debt -1.31Cr -13.81L -11.92L -11.2L -10.19L -19.16L -13Cr -19.47L -51.33L -6.61Cr -51.83L -50.71L -22Cr -1.07Cr -11.29L -10L -9L -8L -15.67L -11Cr -15.92L -41.98L -5.41Cr -42.39L -41.47L -18Cr
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
14/26/14 SEK 0.0359 -7.47% 17,84,111
13/26/13 SEK 0.0388 +4.58% 15,72,171
12/26/12 SEK 0.0371 -5.12% 42,53,816
11/26/11 SEK 0.0391 -0.51% 22,84,399
10/26/10 SEK 0.0393 +3.42% 58,21,668
  1. Stock Market
  2. Stocks
  3. SPEC Stock